Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients
- PMID: 8420443
- DOI: 10.7326/0003-4819-118-4-199302150-00003
Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients
Abstract
Objective: To determine the incidence and clinical course of veno-occlusive disease of the liver (VOD) after bone marrow transplantation and to analyze risk factors for severe VOD.
Design: Cohort study of 355 consecutive patients.
Setting: A bone marrow transplantation center.
Measurements: Each patient was prospectively evaluated for VOD, and many risk factors for severe VOD were analyzed using logistic regression models. The relation of VOD to renal and cardiopulmonary failure was analyzed using time-dependent proportional hazards models.
Results: Veno-occlusive disease developed in 190 of 355 patients (54%; 95% CI, 48% to 59%): Fifty-four patients had severe VOD and 136 had mild or moderate VOD. Independent variables derived from a multivariate model for predicting severe VOD included elevated transaminase values before transplantation (relative risk, 4.6; P < 0.0001); vancomycin therapy during cytoreductive therapy (relative risk, 2.9; P = 0.003); cytoreductive therapy with a high-dose regimen (relative risk, 2.8; P = 0.01); acyclovir therapy before transplantation (relative risk, 4.8; P = 0.02); mismatched or unrelated donor marrow (relative risk, 2.4; P = 0.02); and previous radiation therapy to the abdomen (relative risk, 2.2; P = 0.04). Vancomycin therapy was a marker for persistent fever. Multiorgan failure was more frequent among patients with VOD and usually followed the onset of liver disease.
Conclusions: Veno-occlusive disease, which developed in 54% of bone marrow transplant recipients, is frequently associated with renal and cardiopulmonary failure. Pretransplant transaminase elevations, use of high-dose cytoreductive therapy, and persistent fever during cytoreductive therapy are independent predictors of severe VOD.
Similar articles
-
Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.Blood. 1998 Nov 15;92(10):3599-604. Blood. 1998. PMID: 9808553
-
Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.Bone Marrow Transplant. 1998 Dec;22(12):1191-7. doi: 10.1038/sj.bmt.1701506. Bone Marrow Transplant. 1998. PMID: 9894723
-
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.Biol Blood Marrow Transplant. 1999;5(5):306-15. doi: 10.1016/s1083-8791(99)70006-6. Biol Blood Marrow Transplant. 1999. PMID: 10534061 Clinical Trial.
-
Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.Bone Marrow Transplant. 1992 Sep;10(3):197-214. Bone Marrow Transplant. 1992. PMID: 1422475 Review.
-
Veno-occlusive disease of the liver complicating bone marrow transplantation.Bone Marrow Transplant. 1994 Jan;13(1):1-4. Bone Marrow Transplant. 1994. PMID: 8019444 Review.
Cited by
-
Tolvaptan as an alternative treatment for refractory fluid retention associated with sinusoidal obstruction syndrome after allogeneic stem cell transplantation.Int J Hematol. 2013 Feb;97(2):284-6. doi: 10.1007/s12185-012-1248-x. Epub 2013 Jan 8. Int J Hematol. 2013. PMID: 23297121
-
Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.Int J Clin Oncol. 2022 Nov;27(11):1780-1790. doi: 10.1007/s10147-022-02235-4. Epub 2022 Aug 30. Int J Clin Oncol. 2022. PMID: 36042137 Free PMC article.
-
Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.Ann Hematol. 2021 Jan;100(1):209-216. doi: 10.1007/s00277-020-04312-y. Epub 2020 Oct 23. Ann Hematol. 2021. PMID: 33098041 Free PMC article. Clinical Trial.
-
Successful treatment of severe sinusoidal obstruction syndrome despite multiple organ failure with defibrotide after allogeneic stem cell transplantation: a case report.J Med Case Rep. 2009 Mar 10;3:6164. doi: 10.4076/1752-1947-3-6164. J Med Case Rep. 2009. PMID: 19830097 Free PMC article.
-
A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation.BMC Mol Cell Biol. 2022 Jan 21;23(1):5. doi: 10.1186/s12860-021-00402-5. BMC Mol Cell Biol. 2022. PMID: 35062878 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical